Capecitabine-induced systemic lupus erythematosus and palmoplantar erythrodysesthesia

Alison Wiesenthal, Ryan Matherne, Bernard Gibson

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Capecitabine is emerging as an important drug in the treatment of metastatic breast and colorectal cancers. Marketed as Xeloda ®, this prodrug is taken orally and readily absorbed. It is novel in its increased convenience for patients, similar efficacy to the intravenous form of its active metabolite and its increased tolerability.1 We present a woman with metastatic breast cancer who presented with cutaneous abnormalities two months after starting treatment with capecitabine. Various dermatologic side effects have been attributed to capecitabine, often requiring cessation of the offending drug. We describe an unreported dermatological side effect of capecitabine therapy, systemic lupus erythematosus concurrent with palmoplantar erythrodysesthesia. As the use of this chemotherapeutic agent becomes more prevalent, it is important to recognize the range of its cutaneous side effects.

Original languageEnglish (US)
Pages (from-to)769-771
Number of pages3
JournalJournal of Drugs in Dermatology
Volume11
Issue number6
StatePublished - Jun 2012

Fingerprint

Systemic Lupus Erythematosus
Skin Abnormalities
Breast Neoplasms
Prodrugs
Pharmaceutical Preparations
Colorectal Neoplasms
Therapeutics
Capecitabine
Skin

ASJC Scopus subject areas

  • Dermatology

Cite this

Capecitabine-induced systemic lupus erythematosus and palmoplantar erythrodysesthesia. / Wiesenthal, Alison; Matherne, Ryan; Gibson, Bernard.

In: Journal of Drugs in Dermatology, Vol. 11, No. 6, 06.2012, p. 769-771.

Research output: Contribution to journalArticle

@article{efcd99f543a647bb96aae40c0a5ddec7,
title = "Capecitabine-induced systemic lupus erythematosus and palmoplantar erythrodysesthesia",
abstract = "Capecitabine is emerging as an important drug in the treatment of metastatic breast and colorectal cancers. Marketed as Xeloda {\circledR}, this prodrug is taken orally and readily absorbed. It is novel in its increased convenience for patients, similar efficacy to the intravenous form of its active metabolite and its increased tolerability.1 We present a woman with metastatic breast cancer who presented with cutaneous abnormalities two months after starting treatment with capecitabine. Various dermatologic side effects have been attributed to capecitabine, often requiring cessation of the offending drug. We describe an unreported dermatological side effect of capecitabine therapy, systemic lupus erythematosus concurrent with palmoplantar erythrodysesthesia. As the use of this chemotherapeutic agent becomes more prevalent, it is important to recognize the range of its cutaneous side effects.",
author = "Alison Wiesenthal and Ryan Matherne and Bernard Gibson",
year = "2012",
month = "6",
language = "English (US)",
volume = "11",
pages = "769--771",
journal = "Journal of Drugs in Dermatology",
issn = "1545-9616",
publisher = "Journal of Drugs in Dermatology",
number = "6",

}

TY - JOUR

T1 - Capecitabine-induced systemic lupus erythematosus and palmoplantar erythrodysesthesia

AU - Wiesenthal, Alison

AU - Matherne, Ryan

AU - Gibson, Bernard

PY - 2012/6

Y1 - 2012/6

N2 - Capecitabine is emerging as an important drug in the treatment of metastatic breast and colorectal cancers. Marketed as Xeloda ®, this prodrug is taken orally and readily absorbed. It is novel in its increased convenience for patients, similar efficacy to the intravenous form of its active metabolite and its increased tolerability.1 We present a woman with metastatic breast cancer who presented with cutaneous abnormalities two months after starting treatment with capecitabine. Various dermatologic side effects have been attributed to capecitabine, often requiring cessation of the offending drug. We describe an unreported dermatological side effect of capecitabine therapy, systemic lupus erythematosus concurrent with palmoplantar erythrodysesthesia. As the use of this chemotherapeutic agent becomes more prevalent, it is important to recognize the range of its cutaneous side effects.

AB - Capecitabine is emerging as an important drug in the treatment of metastatic breast and colorectal cancers. Marketed as Xeloda ®, this prodrug is taken orally and readily absorbed. It is novel in its increased convenience for patients, similar efficacy to the intravenous form of its active metabolite and its increased tolerability.1 We present a woman with metastatic breast cancer who presented with cutaneous abnormalities two months after starting treatment with capecitabine. Various dermatologic side effects have been attributed to capecitabine, often requiring cessation of the offending drug. We describe an unreported dermatological side effect of capecitabine therapy, systemic lupus erythematosus concurrent with palmoplantar erythrodysesthesia. As the use of this chemotherapeutic agent becomes more prevalent, it is important to recognize the range of its cutaneous side effects.

UR - http://www.scopus.com/inward/record.url?scp=84863542458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863542458&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 769

EP - 771

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

SN - 1545-9616

IS - 6

ER -